These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 25444872)
21. In Vitro Inhibition of Replication of Dengue Virus Serotypes 1-4 by siRNAs Bound to Non-Toxic Liposomes. Rodriguez-Salazar CA; Recalde-Reyes DP; Bedoya JP; Padilla-Sanabria L; Castaño-Osorio JC; Giraldo MI Viruses; 2022 Feb; 14(2):. PubMed ID: 35215929 [TBL] [Abstract][Full Text] [Related]
22. In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. López C; Gil L; Lazo L; Menéndez I; Marcos E; Sánchez J; Valdés I; Falcón V; de la Rosa MC; Márquez G; Guillén G; Hermida L Arch Virol; 2009; 154(4):695-8. PubMed ID: 19305942 [TBL] [Abstract][Full Text] [Related]
23. The activity of Aurora kinase B is required for dengue virus release. Pérez-Olais JH; Ruiz-Jiménez F; Calderón-Garcia EJ; De Jesús-González LA; Hernández-Rivas R; Del Angel RM Virus Res; 2019 Dec; 274():197777. PubMed ID: 31626875 [TBL] [Abstract][Full Text] [Related]
24. Production and characterization of anti-dengue capsid antibodies suggesting the N terminus region covering the first 20 amino acids of dengue virus capsid protein is predominantly immunogenic in mice. Puttikhunt C; Ong-Ajchaowlerd P; Prommool T; Sangiambut S; Netsawang J; Limjindaporn T; Malasit P; Kasinrerk W Arch Virol; 2009; 154(8):1211-21. PubMed ID: 19565324 [TBL] [Abstract][Full Text] [Related]
25. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. Choi KM; Choi SH; Jeon H; Kim IS; Ahn HJ ACS Nano; 2011 Nov; 5(11):8690-9. PubMed ID: 21985460 [TBL] [Abstract][Full Text] [Related]
27. A cocrystal structure of dengue capsid protein in complex of inhibitor. Xia H; Xie X; Zou J; Noble CG; Russell WK; Holthauzen LMF; Choi KH; White MA; Shi PY Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17992-18001. PubMed ID: 32669438 [TBL] [Abstract][Full Text] [Related]
28. Expression and purification of dengue virus NS5 polymerase and development of a high-throughput enzymatic assay for screening inhibitors of dengue polymerase. Gong EY; Kenens H; Ivens T; Dockx K; Vermeiren K; Vandercruyssen G; Devogelaere B; Lory P; Kraus G Methods Mol Biol; 2013; 1030():237-47. PubMed ID: 23821273 [TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. Subramanya S; Kim SS; Abraham S; Yao J; Kumar M; Kumar P; Haridas V; Lee SK; Shultz LD; Greiner D; N M; Shankar P J Virol; 2010 Mar; 84(5):2490-501. PubMed ID: 20015996 [TBL] [Abstract][Full Text] [Related]
30. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Tay MY; Fraser JE; Chan WK; Moreland NJ; Rathore AP; Wang C; Vasudevan SG; Jans DA Antiviral Res; 2013 Sep; 99(3):301-6. PubMed ID: 23769930 [TBL] [Abstract][Full Text] [Related]
31. Sustained replication of dengue pseudoinfectious virus lacking the capsid gene by trans-complementation in capsid-producing mosquito cells. Sangiambut S; Suphatrakul A; Sriburi R; Keelapang P; Puttikhunt C; Kasinrerk W; Malasit P; Sittisombut N Virus Res; 2013 Jun; 174(1-2):37-46. PubMed ID: 23466247 [TBL] [Abstract][Full Text] [Related]
32. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. Xu M; Hadinoto V; Appanna R; Joensson K; Toh YX; Balakrishnan T; Ong SH; Warter L; Leo YS; Wang CI; Fink K J Immunol; 2012 Dec; 189(12):5877-85. PubMed ID: 23152560 [TBL] [Abstract][Full Text] [Related]
33. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus. Yang CC; Tsai MH; Hu HS; Pu SY; Wu RH; Wu SH; Lin HM; Song JS; Chao YS; Yueh A Antiviral Res; 2013 May; 98(2):228-41. PubMed ID: 23499649 [TBL] [Abstract][Full Text] [Related]
34. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Diamond MS; Harris E Virology; 2001 Oct; 289(2):297-311. PubMed ID: 11689052 [TBL] [Abstract][Full Text] [Related]
35. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Khanam S; Etemad B; Khanna N; Swaminathan S Am J Trop Med Hyg; 2006 Feb; 74(2):266-77. PubMed ID: 16474083 [TBL] [Abstract][Full Text] [Related]
36. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Marcos E; Gil L; Lazo L; Izquierdo A; Brown E; Suzarte E; Valdés I; García A; Méndez L; Guzmán MG; Guillén G; Hermida L Arch Virol; 2013 Jan; 158(1):225-30. PubMed ID: 22983185 [TBL] [Abstract][Full Text] [Related]
37. Attenuated dengue 2 viruses with deletions in capsid protein derived from an infectious full-length cDNA clone. Zhu W; Qin C; Chen S; Jiang T; Yu M; Yu X; Qin E Virus Res; 2007 Jun; 126(1-2):226-32. PubMed ID: 17412442 [TBL] [Abstract][Full Text] [Related]
38. Kinetics of the association of dengue virus capsid protein with the granular component of nucleolus. Tiwary AK; Cecilia D Virology; 2017 Feb; 502():48-55. PubMed ID: 27992765 [TBL] [Abstract][Full Text] [Related]
39. Properties and Functions of the Dengue Virus Capsid Protein. Byk LA; Gamarnik AV Annu Rev Virol; 2016 Sep; 3(1):263-281. PubMed ID: 27501261 [TBL] [Abstract][Full Text] [Related]
40. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen. Batra G; Talha SM; Nemani SK; Dhar N; Swaminathan S; Khanna N Protein Expr Purif; 2010 Nov; 74(1):99-105. PubMed ID: 20435144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]